Title : Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.

Pub. Date : 2014 Nov

PMID : 25104092






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Platinum methylenetetrahydrofolate reductase Homo sapiens
2 The results indicate that a heterozygous advantage may exist in certain MTHFR variants, and the polymorphisms (especially rs1537514) may play a predictive role of treatment efficacy and adverse effects in NSCLC patients treated with platinum-based chemotherapy. Platinum methylenetetrahydrofolate reductase Homo sapiens